TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26362286
Drug: Resveratrol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol treatment
Study: 19819469
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg of MgSO(4)
Study: 19819469
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg of MgSO(4)
Study: 12453969
Drug: Iron depletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron depletion (three extractions of 500 ml blood at 2-week intervals; group 1A)
Study: 7555551
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 to 300 mg three times daily)
Study: 12712782
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion
Study: 11800047
Drug: Diphenhydramine (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (placebo control) infusion
Study: 9479922
Drug: Monitored chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitored chlorhexidine (CHX) gel treatment (3 x 5 min 1% CHX gel, monitored over 12 weeks)
Study: 9479922
Drug: Conventional two-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional two-day CHX treatment (3 x 5 min 1% CHX gel on two consecutive days)
Study: 2537095
Drug: enalapril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (10-20 mg/day)
Study: 242030
Drug: Neoston (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoston (2 g, taken as two times two pills orally 2 and 5 hrs before tests)
Study: 242030
Drug: Neoston (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoston (2 g)
Study: 31218713
Drug: Topical glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoids (mometasone furoate, 100 µg in each nostril once daily) and saline irrigation (150 mL twice a day) for 2 weeks
Study: 31218713
Drug: Inhalation aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aerosol therapy composed of essential oils, saline, glucocorticoids, and antibiotics, once daily 5 times per week for 2 weeks
Study: 25074688
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg twice daily for 24 weeks plus placebo injection every 2 weeks (Arm A)
Study: 25074688
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg twice daily for 4 weeks, then 150 mg once daily up to Week 24 plus placebo injection every 2 weeks (Arm B)
Study: 25074688
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg twice daily for 4 weeks, then 100 mg once daily up to Week 24 plus placebo injection every 2 weeks (Arm C)
Study: 25074688
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every 2 weeks for 24 weeks plus oral placebo twice daily (Arm D)
Study: 25074688
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo twice daily for 6 weeks, plus placebo injection every 2 weeks, then a switch to arm A or B (Arm E)
Study: 21450019
Drug: SNB after
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNB after primary chemotherapy
Study: 18640474
Drug: Levalbuterol 1.25
Normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol 1.25 mg q6-8h
Study: 18640474
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol 2.5 mg q1-4h
Study: 12737671
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose oral contraceptives (specific types not detailed)
Study: 10709162
Drug: 201 mg
Normalized name: ubidecarenone/vit E acet 100 mg-201 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 201 mg fenofibrate + 40 mg pravastatin
Study: 10709162
Drug: 201 mg
Normalized name: ubidecarenone/vit E acet 100 mg-201 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 201 mg fenofibrate alone
Study: 10709162
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin alone
Study: 9360431
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone (2 g intravenous prior to surgery)
Study: 9360431
Drug: Multiple-dose cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose cefuroxime (1.5 g intravenous prior to surgery and 750 mg intramuscular every 8 hours for 48 hours)
Study: 31365624
Drug: Fructose (75g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (75g dissolved in 200 mL of mineral water)
Study: 31365624
Drug: Glucose (75g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (75g dissolved in 200 mL of mineral water)
Study: 25453517
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine formula (HMG)
Study: 25453517
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine formula combined with lactulose (HMCLG)
Study: 11871742
Drug: Low-fat content
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat content nutrient formula (ED group) with 3.4 g of fat per 2000-kcal dose
Study: 11871742
Drug: High amount
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High amount of medium-chain triglycerides nutrient formula (TL group) with 55.6 g of fat per 2000-kcal dose
Study: 11092663
Drug: Levosimendan (10‐min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (10‐min intravenous bolus of 3, 6, 12, 24 or 36 microg/kg, followed by a 24‐h infusion of 0.05, 0.1, 0.2, 0.4 or 0.6 microg/kg/min)
Study: 11092663
Drug: Dobutamine (open‐label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (open‐label infusion of 6 microg/kg/min)
Study: 8810934
Drug: Dalteparin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (200 IU kg‐1) given as a once‐daily subcutaneous injection
Study: 8810934
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) aPTT adjusted i.v. infusion for 6 to 10 days
Study: 1412723
Drug: OKT3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 (5 mg/day) for the first 14 postoperative days
Study: 4096744
Drug: Ticlopidine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (750 mg/d)
Study: 30948756
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg L-DOPA
Study: 26584888
Drug: MultiGeneAngio (MGA)
Normalized name: MGA
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MultiGeneAngio (MGA) - a single intra-arterial infusion of transduced autologous venous smooth muscle cells expressing VEGF165 and endothelial cells expressing Ang-1 (Cohort 1: 1 × 10^7, Cohort 2: 2 × 10^7, Cohort 3: 5 × 10^7, Cohort 4: 7 × 10^7)
Study: 22434783
Drug: Twice-weekly, school-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly, school-based, 10-min jumping regime
Study: 22434783
Drug: Twice-weekly, school-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly, school-based, 10-min jumping regime (boys)
Study: 25466242
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg/day)
Study: 15616239
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 1,000 mg/day t.i.d.
Study: 15616239
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 500 mg/day t.i.d.
Study: 12579174
Drug: Suction group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suction group (n = 80) received 4 L min(‐1) O(2) with nasal cannula and expired air was aspired with a Y‐piece suction system
Study: 12579174
Drug: Non-suction group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-suction group (n = 80) received 4 L min(‐1) O(2) with nasal cannula
Study: 10687256
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg daily for 2 years)
Study: 22784842
Drug: Salsalate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3 g daily)
Study: 19404692
Drug: 10‐mg sustained‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg sustained‐release clotrimazole varnish
Study: 19404692
Drug: 10‐mg clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg clotrimazole oral troche
Study: 18225447
Drug: CB1 antagonists;
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB1 antagonists; specific dosage and duration not available
Study: 12038874
Drug: Short- and
Normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short- and long-term inhaled bronchodilators
Study: 12038874
Drug: Theophyllines (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophyllines (intravenous and oral)
Study: 22116799
Drug: Macrolide antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotics
Study: 12038874
Drug: Intravenous immunoglobulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin, cyclosporine, leukotriene antagonists
Study: 9794853
Drug: Drug interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug interventions
Study: 8904473
Drug: IVIG 800
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 800 mg/kg/day for 3 days plus phototherapy
Study: 31046493
Drug: Medicinal plants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal plants used in the treatment of kidney stones
Study: 25431430
Drug: Mindfulness-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based group therapy
Study: 28438147
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (mostly cognitive-based therapy)
Study: 25555830
Drug: Individualized complementary
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized complementary medicine (CM group)
Study: 24303433
Drug: 4ml of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ml of solution containing 1:200000 adrenaline and 2mg/kg tramadol injected in peritonsillar space (Group A)
Study: 21716117
Drug: Prophylactic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic analgesia with sublingual tramadol Hcl (50 mg) and oral lorazepam (1 mg)
Study: 21716117
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam (5 mg) alone
Study: 19247187
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment
Study: 19247187
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment with statin therapy
Study: 19247187
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment in patients with diabetes
Study: 19247187
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment in tobacco smokers
Study: 10694560
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PeCT) - fluorouracil, doxorubicin, and cyclophosphamide
Study: 3005801
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration after a midnight dose of metyrapone (30 mg/kg)
Study: 31870463
Drug: EMIQ® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMIQ® (2 mg aglycone equivalent)/kg body weight
Study: 22269076
Drug: Self-administered stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered stress management training (SSMT)
Study: 20028830
Drug: Partial Reinforcement
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial Reinforcement (full dose 25% to 50% of the time, placebo other times)
Study: 20028830
Drug: Dose Control
Normalized name: Assure Dose Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Control (continuous reinforcement with 25% to 50% of the initial dose)
Study: 20028830
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy (active drug every treatment with 100% of the initial dose)
Study: 20028830
Drug: Dose Control
Normalized name: Assure Dose Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Control
Study: 20028830
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy
Study: 18400458
Drug: Internal ports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal ports with topical anesthetic
Study: 16258594
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline 5 ml (Group A)
Study: 16258594
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 microg/kg + dexamethasone 8 mg (Group B)
Study: 16258594
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 microg/kg + droperidol 1.25 mg (Group C)
Study: 16258594
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg (Group D)
Study: 7781632
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anaesthesia (38.4 mg hyperbaric lignocaine 5%)
Study: 7781632
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia (10.8 mg hyperbaric bupivacaine 0.5%)
Study: 7781632
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anaesthesia
Study: 6998536
Drug: Carbohydrate infusion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate infusion at 0.025 MJ (6 kcal) per kg body weight per 24 h
Study: 6998536
Drug: Carbohydrate infusion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate infusion at 0.105 MJ (25 kcal) per kg body weight per 24 h
Study: 6998536
Drug: Carbohydrate infusion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate infusion at 0.167 MJ (40 kcal) per kg body weight per 24 h
Study: 24765899
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0.2 mg
Study: 9311220
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 ml of 0.9% saline)
Study: 29355292
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection (1 ml Betamethasone)
Study: 29355292
Drug: Direct approach
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct approach corticosteroid injection (1 ml Betamethasone)
Study: 28129555
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) or acceptance and commitment therapy (ACT) for 12 weeks
Study: 23398459
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 0.1% ointment applied twice weekly
Study: 23398459
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E applied once daily
Study: 23398459
Drug: Cold cream
Normalized name: cold cream
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold cream applied once daily
Study: 23578980
Drug: Indacaterol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 300 μg once-daily
Study: 18653310
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavior therapy (CBT)
Study: 16551272
Drug: Flavanol-rich chocolate
Normalized name: RESOURCE INSTANT CRYSTALS (RICH CHOCOLATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich chocolate bar and cocoa beverage daily (total flavanols, 444 mg/day)
Study: 16551272
Drug: Matching isocaloric
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching isocaloric placebos daily (total flavanols, 19.6 mg/day)
Study: 12939717
Drug: Rituximab (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (given weekly as a single agent)
Study: 12939717
Drug: Rituximab (thrice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (thrice-weekly dosing schedule)
Study: 12939717
Drug: Rituximab concurrent
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab concurrent with fludarabine
Study: 12939717
Drug: Rituximab with
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab with appropriate premedication and a stepped up dosing schedule
Study: 10940817
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream A (dissolved)
Study: 10940817
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream B (dispersed)
Study: 9221629
Drug: Regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional treatment (portal vein or intraperitoneal) combined with systemic chemotherapy
Study: 9221629
Drug: Immunotherapy (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (autologous tumor cell-BCG or monoclonal antibody treatment)
Study: 6299652
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily
Study: 3307550
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/kg)
Study: 29388288
Drug: Dexmedetomidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (2 μg/kg)
Study: 29388288
Drug: Control (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (40 mL of 0.25% bupivacaine)
Study: 1441863
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus adrenaline 75 mg + 150 micrograms
Study: 1441863
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus adrenaline 50 mg + 100 micrograms
Study: 1441863
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus adrenaline 25 mg + 50 micrograms
Study: 1441863
Drug: Postoperative analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesics administration
Study: 21318060
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injection at bedtime (21:00-24:00)
Study: 21318060
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injection at breakfast (06:00-09:00)
Study: 10592547
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (TM)
Study: 10592547
Drug: Not treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not treated with medication
Study: 8947980
Drug: Intranasal metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal metoclopramide 20 mg
Study: 2567792
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose aspirin plus dipyridamole
Study: 1226582
Drug: VK744 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: VK744 (300 mg TID for 2 days before, 5 days during, 3 days after saturation dive)
Study: 21512889
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation [1.5 g/d n‐3 LCPUFA]
Study: 23079140
Drug: Palatal implant
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal implant (PI) supported anchorage
Study: 12362799
Drug: Iron solution
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron solution plus ascorbic acid added to domestic drinking water
Study: 7979623
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B in traditional incremental dose regimen (0.05, 0.10, 0.25, 0.50 and 1.0 mg/kg body weight on days 1, 2, 3, 4, and > 4)
Study: 7979623
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B at a constant 1 mg/kg bodyweight per day from day 1
Study: 7979623
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (incremental and constant dose)
Study: 10070911
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron treatment
Study: 1192712
Drug: Frusemide 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 120 nmol (40 mg) administered intravenously
Study: 1192712
Drug: Frusemide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 60 nmol (20 mg) administered intravenously
Study: 24761394
Drug: Symbicort 80/4.5
Normalized name: Symbicort 80/4.5 Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort 80/4.5 mg/inhalation, two puffs twice daily
Study: 24761394
Drug: Symbicort 160/4.5
Normalized name: Symbicort 160/4.5 Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort 160/4.5 mg/inhalation, two puffs twice daily
Study: 24761394
Drug: Pulmicort 180
Normalized name: Pulmicort
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort 180 mcg/inhalation, two puffs twice daily
Study: 23720894
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine plus MDT
Study: 18697469
Drug: 1-month depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month depot (Zoladex 3.6 mg)